Abstract PS2-02-30: Five-year survival outcomes after systemic therapy in older patients with early-stage triple negative breast cancer at memorial sloan kettering cancer center

Abstract INTRODUCTION: Approximately 15% cases of Triple Negative Breast Cancer (TNBC) are diagnosed in individuals over the age of 70. Older patients remain underrepresented in clinical trials. We conducted a retrospective review of patients to describe the clinical practice patterns and outcomes in patients aged ≥70 years with stage I-III TNBC who were treated at Memorial Sloan Kettering Cancer Center (MSKCC). MATERIAL AND METHODS: Medical records of patients with patients aged ≥ 70 years diagnosed with stage I-III triple negative breast cancer from January 1st, 2015, through December 31st, 2019, were abstracted. Charts were analyzed for patient demographics, cancer stage, pathology reports, surgical and systemic therapy data. Chemotherapy (C) and non-chemotherapy (NC) groups were compared based on baseline characteristics, toxicities, and outcomes. We compared patient characteristics by chemotherapy type using Wilcoxon rank sum test, Pearson’s Chi-squared test, and Fisher’s exact test. Overall Survival (OS), Breast Cancer Specific Survival (BCSS), and Recurrence Free BCSS (RF-BCSS) were examined using Cox proportional hazards models. All statistical analyses were conducted using R. RESULTS: Total 144 patients were included in our data analysis. The median age of participants was 75 years (range 70-96). The number of patients with stage I, II, and III disease was 61 (42%), 66 (46%), and 17 (12%), respectively. NC group was associated with older median age (81 years vs. 74 years (p